1. Mazzucchelli, Renata, and Scott K. Durum. "Interleukin-7 receptor expression: intelligent design." Nature Reviews Immunology 7.2 (2007): 144-154.
2. Fry, Terry J., and Crystal L. Mackall. "Interleukin-7: from bench to clinic." Blood, The Journal of the American Society of Hematology 99.11 (2002): 3892-3904.
3. Ponchel, Frederique, et al. "Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopenia." Arthritis Res Ther 7.1 (2004): R80.
4. Seddiki, N. Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A, Solomon M, Selby W, Alexander SI, Nanan R, Kelleher A, Fazekas de St Groth B. "Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells." J Exp Med 203 (2006): 1693-1700.
Lymphocytes (ALC) significantly increased (3x over baseline) by week 3 and remained elevated for the duration of the follow-up. Analysis based on 17 evaluable patients.
Lymphocytes (ALC) increased and remain elevated even when patients were receiving chemotherapy (temozolomide, TMZ).
Lymphocytes (ALC) significantly increased (3x over baseline) by week 3 and remained elevated for the duration of the follow-up. Analysis based on 17 evaluable patients.
Lymphocytes (ALC) increased and remain elevated even when patients were receiving chemotherapy (temozolomide, TMZ).
CD4+ and CD8+ T cells, following the same pattern, increased 4x over baseline by week 3 and remained increased until week 9 (last measurement). Analysis based on 17 evaluable patients.
(*p≤0.05; **p≤0.001; ***p≤0.0001; ***p≤0.00001)
Dynamics of the CD8+ T cell subsets after NT-I7 administration. The associated upregulation of Ki67 (data not shown), a marker of cell proliferation, suggests that proliferation, rather than re-distribution, is driving the increase of T cells.
CD4+ and CD8+ T cells, following the same pattern, increased 4x over baseline by week 3 and remained increased until week 9 (last measurement). Analysis based on 17 evaluable patients.
(*p≤0.05; **p≤0.001; ***p≤0.0001; ***p≤0.00001)
Dynamics of the CD8+ T cell subsets after NT-I7 administration. The associated upregulation of Ki67 (data not shown), a marker of cell proliferation, suggests that proliferation, rather than re-distribution, is driving the increase of T cells.
Source: 1) MSS-CRC 2021 SITC; 2) GBM 2021 SITC
Potent chemoattractants and mediators of TLS formation significantly increased after the first NT-I7+pembro dose. These chemokines recruit lymphocytes into the tumor and facilitate T cell anti-tumor activity. Analysis based on 17 evaluable patients. (*p≤0.05; **p≤0.001; ***p≤0.0001; ***p≤0.00001)
Subjects with a higher increase in TILs (y axis) experienced greater tumor reduction (x axis) with treatment.
Subjects with a higher increase in TILs (x axis) had higher overall survival (OS) (y axis).
Wks = weeks
Potent chemoattractants and mediators of TLS formation significantly increased after the first NT-I7+pembro dose. These chemokines recruit lymphocytes into the tumor and facilitate T cell anti-tumor activity. Analysis based on 17 evaluable patients. (*p≤0.05; **p≤0.001; ***p≤0.0001; ***p≤0.00001)
Subjects with a higher increase in TILs (y axis) experienced greater tumor reduction (x axis) with treatment.
Subjects with a higher increase in TILs (x axis) had higher overall survival (OS) (y axis).
Wks = weeks
Source: 1)2021 SITC; 2)NeoImmuneTech, Phase 1, FIH study
Pre-treatment and on-treatment paired biopsies showed a significant increase of CD8+ T cell infiltration by both immunofluorescence and flow cytometry analysis. * p<0.05; ***p<0.0001
Pre-Tx = Pre-treatment & On-Tx = On-treatment.
Representative pre- and on-treatment paired biopsies for a subject with clear cell ovarian cancer. Immunohistochemical staining showed a significant increase of CD8+ T cells (brown) in the on-treatment sample.
Pre-Tx = Pre-treatment & On-Tx = On-treatment.
Representative pre- and on-treatment paired biopsies for a subject with clear cell ovarian cancer. Immunohistochemical staining showed a significant increase of CD8+ T cells (brown) in the on-treatment sample.
Source: 1) MSS-CRC/PaC 2022 ESMO, SITC 2022; 2) 2021 ASCO
Source: MSS-CRC/PaC 2022 ESMO
Source: 2021 SITC